CN107012117B - 可从机体组织分离的多能干细胞 - Google Patents

可从机体组织分离的多能干细胞 Download PDF

Info

Publication number
CN107012117B
CN107012117B CN201611060144.1A CN201611060144A CN107012117B CN 107012117 B CN107012117 B CN 107012117B CN 201611060144 A CN201611060144 A CN 201611060144A CN 107012117 B CN107012117 B CN 107012117B
Authority
CN
China
Prior art keywords
cells
cell
muse
pluripotent stem
clusters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201611060144.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107012117A (zh
Inventor
出泽真理
藤吉好则
锅岛阳一
若尾昌平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Muse Cell Innovation Co.,Ltd.
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107012117(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CN107012117A publication Critical patent/CN107012117A/zh
Application granted granted Critical
Publication of CN107012117B publication Critical patent/CN107012117B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN201611060144.1A 2009-07-15 2010-07-15 可从机体组织分离的多能干细胞 Active CN107012117B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21378809P 2009-07-15 2009-07-15
US61/213788 2009-07-15
US29015909P 2009-12-24 2009-12-24
US61/290159 2009-12-24
CN201080041908.7A CN102858951B (zh) 2009-07-15 2010-07-15 可从机体组织分离的多能干细胞

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080041908.7A Division CN102858951B (zh) 2009-07-15 2010-07-15 可从机体组织分离的多能干细胞

Publications (2)

Publication Number Publication Date
CN107012117A CN107012117A (zh) 2017-08-04
CN107012117B true CN107012117B (zh) 2020-10-23

Family

ID=43449509

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080041908.7A Active CN102858951B (zh) 2009-07-15 2010-07-15 可从机体组织分离的多能干细胞
CN201611060144.1A Active CN107012117B (zh) 2009-07-15 2010-07-15 可从机体组织分离的多能干细胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201080041908.7A Active CN102858951B (zh) 2009-07-15 2010-07-15 可从机体组织分离的多能干细胞

Country Status (16)

Country Link
US (1) US9550975B2 (enExample)
EP (3) EP2455452B2 (enExample)
JP (7) JP5185443B2 (enExample)
KR (4) KR101945343B1 (enExample)
CN (2) CN102858951B (enExample)
AU (1) AU2010271722B8 (enExample)
CA (1) CA2768238C (enExample)
DK (2) DK3214170T3 (enExample)
ES (3) ES2831030T3 (enExample)
HR (1) HRP20250245T1 (enExample)
HU (3) HUE071170T2 (enExample)
NO (1) NO2455452T3 (enExample)
PL (3) PL2455452T5 (enExample)
PT (2) PT3214170T (enExample)
SG (1) SG177705A1 (enExample)
WO (1) WO2011007900A1 (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550975B2 (en) * 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
US9399758B2 (en) 2009-07-15 2016-07-26 Mari Dezawa SSEA3(+) pluripotent stem cell that can be isolated from body tissue
JP2014133703A (ja) * 2011-03-30 2014-07-24 Clio Inc 生体組織から単離できるｓｓｅａ−３陽性の多能性幹細胞を含む他家移植用細胞治療用組成物
JP2014132830A (ja) * 2011-03-30 2014-07-24 Clio Inc 生体の臍帯又は脂肪組織から単離できる多能性幹細胞
US8883430B2 (en) 2009-08-21 2014-11-11 The Board Of Trustees Of The Leland Stanford Junior University Enhanced efficiency of induced pluripotent stem cell generation from human somatic cells
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
KR102073530B1 (ko) * 2011-06-06 2020-02-04 리제네시스 비브이비에이 중공 섬유 생물 반응기에서의 줄기 세포의 확장
WO2013015457A1 (en) 2011-07-27 2013-01-31 Kyoto University Novel markers for dopaminergic neuron progenitor cells
KR101751355B1 (ko) 2011-08-24 2017-07-04 (주)아모레퍼시픽 인간 피부 진피 유래 성체 줄기세포
JP6162604B2 (ja) 2011-10-21 2017-07-12 国立大学法人京都大学 層流による多能性維持単一分散細胞培養法
AU2013230653A1 (en) * 2012-03-06 2014-10-23 Sct&B Inc. Placental stem cells, methods for isolating same and use thereof
WO2013163296A1 (en) * 2012-04-24 2013-10-31 The Brigham And Women's Hospital, Inc. Generating pluripotent cells de novo
EP2877577A4 (en) * 2012-07-27 2016-02-10 Bioquark Inc ELECTROPORATED AMPHIBIENOO CYTS ISOLATED EXTRACTS AND THEIR USE FOR THE TREATMENT OF ILLNESSES AND DISORDERS
WO2014027474A1 (ja) * 2012-08-17 2014-02-20 株式会社Ｃｌｉｏ 心筋梗塞の修復再生を誘導する多能性幹細胞
US20150329827A1 (en) * 2012-12-21 2015-11-19 Rutgers , The State University Of New Jersey Muse cells isolation and expansion
US9709554B2 (en) 2013-01-31 2017-07-18 Rutgers, The State University Of New Jersey In vitro model of macrosteatotic (fatty) liver
JP6495658B2 (ja) 2013-02-08 2019-04-03 国立大学法人京都大学 巨核球及び血小板の製造方法
WO2014133090A1 (ja) * 2013-02-28 2014-09-04 国立大学法人浜松医科大学 脳腫瘍治療のための多能性幹細胞
KR102180319B1 (ko) * 2013-03-01 2020-11-18 가부시키가이샤 클리오 다능성 줄기세포를 손상부위로 유도하는 유주인자를 포함하는 의약조성물
TW201522637A (zh) * 2013-03-15 2015-06-16 Jackson Lab 非胚胎幹細胞之單離及其用途
EP2977449B1 (en) 2013-03-21 2020-02-26 Kyoto University Pluripotent stem cell for neuronal differentiation induction
WO2014157257A1 (ja) 2013-03-25 2014-10-02 公益財団法人先端医療振興財団 細胞の選別方法
JP6461787B2 (ja) 2013-04-12 2019-01-30 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
JP6429280B2 (ja) 2013-05-14 2018-11-28 国立大学法人京都大学 効率的な心筋細胞の誘導方法
WO2014190150A1 (en) * 2013-05-22 2014-11-27 The Regents Of The University Of California Pluripotent human adipose adult stem cells: isolation, characterization and clinical implications
US20150037436A1 (en) 2013-07-30 2015-02-05 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US9796962B2 (en) 2013-08-07 2017-10-24 Kyoto University Method for generating pancreatic hormone-producing cells
US10265347B2 (en) 2013-08-29 2019-04-23 Norimasa Miura Biomolecular group related to cell anti-aging
CA2921948C (en) 2013-09-04 2019-11-19 Otsuka Pharmaceutical Factory, Inc. Method for preparing pluripotent stem cells
SG11201601720RA (en) 2013-09-05 2016-04-28 Univ Kyoto New method for inducing dopamine-producing neural precursor cells
JP6635505B2 (ja) 2013-11-01 2020-01-29 国立大学法人京都大学 新規軟骨細胞誘導方法
US9987310B2 (en) 2013-11-27 2018-06-05 University Of Louisville Research Foundation, Inc. Cardiac progenitor cells and methods of use therefor
JP6519038B2 (ja) * 2014-02-26 2019-05-29 株式会社生命科学インスティテュート 脳梗塞治療のための多能性幹細胞
JP2015160820A (ja) * 2014-02-26 2015-09-07 株式会社Ｃｌｉｏ 慢性腎障害治療のための多能性幹細胞
RU2711942C2 (ru) 2014-03-19 2020-01-23 Виселл Терапеутикс, Инк. Способы, относящиеся к плюрипотентным клеткам
WO2015178431A1 (ja) 2014-05-21 2015-11-26 国立大学法人京都大学 膵芽細胞の製造方法および膵芽細胞を含む膵疾患治療剤
KR101592401B1 (ko) * 2014-06-13 2016-02-05 주식회사 비비에이치씨 지방-유래 중간엽 줄기세포로부터 유도만능 줄기세포를 제조하는 방법 및 그 방법에 의해 제조된 유도만능 줄기세포
JP6391364B2 (ja) * 2014-08-25 2018-09-19 国立大学法人 鹿児島大学 認知機能障害改善用細胞製剤
JP6452107B2 (ja) * 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
KR101700598B1 (ko) * 2014-11-11 2017-01-31 한국원자력의학원 Cd105를 포함하는 줄기세포능을 가진 섬유아세포 분리용 바이오마커 조성물 및 이를 이용한 줄기세포능을 가진 섬유아세포 분리 방법
EP3297694A1 (en) 2015-05-21 2018-03-28 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
HK1249862A1 (en) * 2015-05-29 2018-11-16 Nippon Zoki Pharmaceutical Co., Ltd. Pluripotent stem cell migration promoter
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
JP6627027B2 (ja) * 2015-09-11 2020-01-08 福美人株式会社 皮膚細胞の活性化作用を呈するフラボノイド誘導体
CA3011333C (en) * 2016-01-15 2022-01-25 University Of Toyama Mobilization of pluripotent stem cells for ischemic cerebral infarction
JP6770673B2 (ja) * 2016-02-26 2020-10-21 国立大学法人東海国立大学機構 急性心筋梗塞の予後マーカー及びその利用
KR102313628B1 (ko) * 2016-03-17 2021-10-15 시노바 라이프 사이언시즈 인코포레이티드 충격파 또는 기계적 충격을 사용한 세포의 분리, 해리 및/또는 탈응집
US11898163B2 (en) 2016-04-22 2024-02-13 Kyoto University Method for producing dopaminergic neuron progenitor cell
WO2017199976A1 (ja) * 2016-05-16 2017-11-23 国立大学法人名古屋大学 多能性幹細胞による周産期脳障害の改善及び治療
JP7618191B2 (ja) 2016-07-01 2025-01-21 国立大学法人東北大学 臓器線維症の予防または治療剤
EP3492091B1 (en) * 2016-07-29 2021-07-14 Tohoku University "muse" cells as prophylactic or therapeutic agent for aneurysm
WO2018025973A1 (ja) 2016-08-03 2018-02-08 国立大学法人名古屋大学 多能性幹細胞による慢性肺疾患の改善及び治療
US11920180B2 (en) 2016-08-03 2024-03-05 Tohoku University Method for inducing differentiation of pluripotent stem cells in vitro
EP3494979B1 (en) 2016-08-03 2025-07-09 Yabuki, Hiroshi Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
SG11201907134VA (en) 2017-02-03 2019-09-27 Univ Kyushu Nat Univ Corp Method for preparing dental pulp stem cells from cells derived from dental pulp tissue
JP7181534B2 (ja) * 2017-03-28 2022-12-01 味の素株式会社 未分化維持培地添加剤
JP7712643B2 (ja) * 2017-06-19 2025-07-24 国立大学法人東北大学 表皮水疱症の治療剤
SG11201912831TA (en) 2017-06-20 2020-01-30 Univ Nagoya Nat Univ Corp Amelioration and treatment of brain disorder resulting from fetal growth retardation using pluripotent stem cells
AU2018352904A1 (en) * 2017-10-17 2020-05-21 Hiroshima University Pluripotent stem cells inducing osteochondral repair
RU2730864C1 (ru) * 2017-11-10 2020-08-26 Редженесис Сайенс Ко., Лтд. Способ производства культивируемых клеток и лекарственного препарата для лечения спинномозговых травм
KR102145929B1 (ko) 2017-11-28 2020-08-20 주식회사 셀투인 실시간 글루타치온 측정을 통한 치료용 세포의 품질 측정 방법
JP6604492B2 (ja) * 2018-04-09 2019-11-13 株式会社生命科学インスティテュート 脳梗塞治療のための多能性幹細胞
CA3099661A1 (en) * 2018-05-09 2019-11-14 Life Science Institute, Inc. Therapeutic agent for spinal cord injury
JP7072777B2 (ja) * 2018-07-03 2022-05-23 株式会社生命科学インスティテュート 慢性腎障害治療のための多能性幹細胞
EP3824912A4 (en) 2018-07-19 2022-04-20 Kyoto University PLATEFORM CARTILAGE DERIVED FROM PLURIPOTENTS STEM CELLS AND METHODS FOR PRODUCTION OF PLATEFORM CARTILAGE
US20220025336A1 (en) * 2018-11-14 2022-01-27 Kataoka Corporation Method for producing insulin-producing cells, and composition
AU2019388016B2 (en) * 2018-11-30 2024-12-19 Kyoto Prefectural Public University Corporation Therapeutic agent of peripheral blood flow disorder
EP3900787A4 (en) 2018-12-21 2022-02-23 Kyoto University LUBRICIN-LOCALIZED CARTILE-LIKE TISSUE, METHOD OF MANUFACTURE THEREOF AND COMPOSITION THEREOF FOR TREATMENT OF ARTICULATE-CARTILAGE DEFECTS
CN114026221A (zh) * 2019-04-09 2022-02-08 新泽西鲁特格斯州立大学 富集细胞群的方法
JP7618233B2 (ja) 2019-08-09 2025-01-21 国立大学法人東北大学 脳血管性認知症の治療または予防剤
CA3153237A1 (en) 2019-09-05 2021-03-11 Tohoku University Therapeutic agent for myocarditis
BR112022006286A2 (pt) 2019-10-01 2022-06-21 Univ Kyoto Métodos para isolar uma célula da ponta do broto uretérico, para produzir uma colônia celular da ponta do broto uretérico, para produzir um organoide, para produzir uma célula progenitora do duto de coleta, para produzir uma população celular de ponta do broto uretérico e para monitorar uma célula da ponta do broto uretérico, e, composição para isolar ou monitorar uma célula da ponta do broto uretérico
EP4052718A1 (en) * 2019-10-31 2022-09-07 Life Science Institute, Inc. Therapy for interstitial cystitis by pluripotent stem cells
EP4074321A4 (en) 2019-12-12 2024-01-03 National University Corporation Chiba University Freeze-dried preparation containing megakaryocytes and platelets
AU2021239654A1 (en) 2020-03-19 2022-10-27 Orizuru Therapeutics, Inc. Cardiomyocyte purification method
EP4123016A4 (en) 2020-03-19 2024-06-19 Orizuru Therapeutics, Inc. Method for purifying cardiomyocytes
WO2021201286A1 (ja) 2020-04-02 2021-10-07 国立大学法人東北大学 ハイポテンシャル多能性幹細胞
EP4180516A4 (en) 2020-07-13 2024-01-17 Kyoto University SKELETON MUSCLE PRECURSOR CELLS AND METHOD FOR PURIFICATION THEREOF, COMPOSITION FOR THE TREATMENT OF MYOGENIC DISEASES AND METHOD FOR PRODUCING SKELETON MUSCLE PRECURSOR CELLS CONTAINING CELL GROUPS
WO2022014681A1 (ja) 2020-07-15 2022-01-20 国立大学法人 岡山大学 運動ニューロン疾患（ｍｎｄ）の治療に有効な多能性幹細胞
JP2021073305A (ja) * 2021-02-09 2021-05-13 株式会社生命科学インスティテュート 慢性腎障害治療のための多能性幹細胞
TWI832070B (zh) * 2021-07-15 2024-02-11 國璽幹細胞應用技術股份有限公司 幹細胞製劑用於治療關節炎的用途及用於製備幹細胞製劑的方法
JP2023041486A (ja) * 2021-09-13 2023-03-24 国立大学法人東北大学 毛髪損傷の治療剤
JPWO2023153464A1 (enExample) 2022-02-09 2023-08-17
WO2023228908A1 (ja) 2022-05-23 2023-11-30 国立大学法人京都大学 腎集合管細胞および腎盂上皮細胞の製造方法
CN117187174B (zh) * 2023-11-08 2024-02-06 广州正源生物技术有限公司 一种Muse细胞培养基以及一种脂肪Muse细胞的提取方法
JP2025123077A (ja) * 2024-02-09 2025-08-22 国立大学法人東北大学 脊髄梗塞治療のための多能性幹細胞

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1845987A (zh) * 2003-08-29 2006-10-11 明尼苏达大学董事会 肾来源的干细胞及其分离、分化和使用方法
CN101180389A (zh) * 2005-05-17 2008-05-14 利莱恩斯生命科学有限公司 采用哺乳动物细胞确立人胚胎干细胞系

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1226233T3 (da) 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
US7575921B2 (en) * 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
WO2002057428A1 (en) * 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
JP4182742B2 (ja) 2002-12-12 2008-11-19 日産自動車株式会社 自動車の前部車体構造
US20050042595A1 (en) 2003-08-14 2005-02-24 Martin Haas Banking of multipotent amniotic fetal stem cells
US20060216821A1 (en) * 2004-02-26 2006-09-28 Reliance Life Sciences Pvt. Ltd. Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof
US9388382B2 (en) * 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
AU2006304390A1 (en) 2005-10-17 2007-04-26 Academia Sinica Pulmonary stem cells, related methods and kits
WO2009059032A2 (en) * 2007-10-30 2009-05-07 University Of Louisville Research Foundation, Inc. Uses and isolation of very small embryonic-like (vsel) stem cells
KR101420740B1 (ko) 2005-12-13 2014-07-17 교또 다이가꾸 핵초기화 인자
WO2008080200A1 (en) 2006-12-29 2008-07-10 Irina Kerkis Process for obtaining stem cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US20090172832A1 (en) * 2007-12-28 2009-07-02 Timothy Caspar Expression of rubisco enzyme from a non-rubisco locus
ITRM20080342A1 (it) * 2008-06-26 2009-12-27 Univ Degli Studi Udine Cellule di polpa dentale midollo-simili, metodi per isolamento ed uso.
US9550975B2 (en) 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1845987A (zh) * 2003-08-29 2006-10-11 明尼苏达大学董事会 肾来源的干细胞及其分离、分化和使用方法
CN101180389A (zh) * 2005-05-17 2008-05-14 利莱恩斯生命科学有限公司 采用哺乳动物细胞确立人胚胎干细胞系

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Isolation of Mesenchymal Stem Cells from Human Placental Decidua Basalis and Resistance to Hypoxia and Serum Deprivation;Yong-Can Huang et al;《Stem Cell Rev and Rep》;20090523;第5卷;第247页摘要，第248页左栏第3段，第248页右栏第2段-5段，第253页左栏第1段 *

Also Published As

Publication number Publication date
EP2455452B2 (en) 2020-10-07
US20110070647A1 (en) 2011-03-24
CN107012117A (zh) 2017-08-04
JP5852503B2 (ja) 2016-02-03
EP2455452A4 (en) 2013-11-27
JPWO2011007900A1 (ja) 2012-12-27
KR20150063168A (ko) 2015-06-08
CA2768238C (en) 2017-11-28
PT3214170T (pt) 2020-11-16
US9550975B2 (en) 2017-01-24
KR20160040728A (ko) 2016-04-14
JP7134317B2 (ja) 2022-09-09
KR101764080B1 (ko) 2017-08-01
AU2010271722B2 (en) 2014-05-29
CN102858951B (zh) 2016-12-07
AU2010271722A1 (en) 2012-03-01
JP2021184754A (ja) 2021-12-09
ES2647360T3 (es) 2017-12-21
HUE037448T2 (hu) 2018-09-28
EP2455452B1 (en) 2017-09-06
JP2020058385A (ja) 2020-04-16
ES2831030T3 (es) 2021-06-07
EP2455452A1 (en) 2012-05-23
HRP20250245T1 (hr) 2025-06-20
JP6937821B2 (ja) 2021-09-22
DK2455452T4 (da) 2020-11-02
NO2455452T3 (enExample) 2018-02-03
KR20170089959A (ko) 2017-08-04
SG177705A1 (en) 2012-02-28
JP2018203780A (ja) 2018-12-27
JP6416298B2 (ja) 2018-10-31
AU2010271722B8 (en) 2014-07-03
ES2647360T5 (es) 2021-06-14
PL3680323T3 (pl) 2025-09-01
JP5185443B2 (ja) 2013-04-17
EP3680323B1 (en) 2024-11-27
CN102858951A (zh) 2013-01-02
PL3214170T3 (pl) 2021-04-06
KR101945343B1 (ko) 2019-02-07
HUE052559T2 (hu) 2021-05-28
HUE071170T2 (hu) 2025-08-28
JP2016028614A (ja) 2016-03-03
JP6641441B2 (ja) 2020-02-05
ES3015175T3 (en) 2025-04-29
EP3680323C0 (en) 2024-11-27
JP2012139246A (ja) 2012-07-26
EP3214170B1 (en) 2020-09-02
PL2455452T5 (pl) 2021-01-25
JP6092357B2 (ja) 2017-03-08
WO2011007900A1 (ja) 2011-01-20
PL2455452T3 (pl) 2018-02-28
JP2017122095A (ja) 2017-07-13
CA2768238A1 (en) 2011-01-20
EP3214170A1 (en) 2017-09-06
KR20120069663A (ko) 2012-06-28
KR101651795B1 (ko) 2016-08-26
DK3214170T3 (da) 2020-10-12
DK2455452T3 (en) 2017-10-23
EP3680323A1 (en) 2020-07-15
PT2455452T (pt) 2017-11-20

Similar Documents

Publication Publication Date Title
JP7134317B2 (ja) 生体組織から単離できる多能性幹細胞
US11261426B2 (en) Pluripotent stem cell that can be isolated from body tissue

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250124

Address after: Singapore City

Patentee after: Muse Cell Innovation Co.,Ltd.

Country or region after: Singapore

Address before: Sendai City, Miyagi Prefecture, Japan

Patentee before: Dezawa Mari

Country or region before: Japan

Patentee before: Fujiyoshi Yoshinori

Patentee before: Nabeshima Yo-ichi

Patentee before: Wakao Shohei

Patentee before: KITADA